Both MDM2 and MDM4 are overexpressed in a variety of tumors, which result in the downregulation of p53 protein levels and activities, leading to tumor initiation and/or progression (Karni-Schmidt et al., 2016; Donehower et al., 2019; Haupt et al., 2019). The gene discussed is TP53; the disease is neoplasm.